LUMA trial: A setback, not a defeat

Experimental drug falls short in broad study—but research continues

Biogen and Denali have shared results from the LUMA trial, a study of 648 participants aged 30 to 80 designed to test whether an experimental drug called BIIB122 (DNL151) could slow symptom progression in people with early-stage Parkinson’s. The trial’s main goal was to determine whether people taking the drug had a slower rate of symptom worsening compared to those who received a placebo. Those taking the drug experienced symptom worsening at a similar rate to those who received the placebo, meaning that the drug did not make a meaningful difference for the broader Parkinson’s population. The study included two groups: the general Parkinson’s population and people living with Parkinson’s who carry the LRRK2 genetic variant.

Key facts about the study

  • The Phase 2b trial did not show a meaningful benefit for the general Parkinson’s population.
  • The drug is continuing to be studied in a trial called BEACON for the LRRK2-specific subgroup to determine whether the drug may still offer benefit for people with that genetic variant.
  • The LRRK2 pathway remains one of the most promising targets in Parkinson’s research.
  • Safety data and biomarker insights from this study can still help shape smarter future trials.
  • Other LRRK2-focused programs remain active in the broader Parkinson’s research pipeline.

What is LRRK2 and why does it matter?

LRRK2 is a gene that gives the body instructions for making a protein. In most people, this protein does its job without any issues. But in some people living with Parkinson’s, a change in this gene can cause the protein to behave abnormally, and researchers believe this plays a role in damaging the dopamine neurons that are affected in Parkinson’s. Because scientists can pinpoint exactly what is going wrong at the genetic level, LRRK2 provides them a specific target to aim at when developing new treatments.

This is an important point. Most current Parkinson’s treatments help manage symptoms but do not slow or stop the condition from progressing. A drug that could target abnormal LRRK2 proteins might one day do exactly that—not only treat the symptoms but also address one of the underlying causes.

Why this matters

Drug development is a long, iterative process. While a trial that misses its primary endpoint is a setback, it is certainly not a defeat for the field. LRRK2 remains a compelling target for disease-modifying therapies, and the information generated by the LUMA study will help researchers refine future studies and better understand who may benefit from this kind of treatment.

While such news can be discouraging, it also reinforces the importance of continued research, careful analysis, and persistence in the search for therapies that can slow or stop Parkinson’s progression.

Parkinson Canada was not involved in this trial, but we continue to follow clinical research closely and share updates that matter to our community.

For more details: